Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022
May 23, 2022 at 04:01 pm
Share
Theralink Technologies, Inc. reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported sales was USD 0.0195 million compared to USD 0.126314 million a year ago. Net loss was USD 1.84 million compared to USD 1.36 million a year ago.
For the six months, sales was USD 0.098475 million compared to USD 0.136104 million a year ago. Net loss was USD 3.35 million compared to USD 2.78 million a year ago.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 
